WO2021163490A1 - Appauvrissement ciblé de bactéries à partir de populations mélangées par l'intermédiaire d'une adhérence cellulaire programmable - Google Patents

Appauvrissement ciblé de bactéries à partir de populations mélangées par l'intermédiaire d'une adhérence cellulaire programmable Download PDF

Info

Publication number
WO2021163490A1
WO2021163490A1 PCT/US2021/017866 US2021017866W WO2021163490A1 WO 2021163490 A1 WO2021163490 A1 WO 2021163490A1 US 2021017866 W US2021017866 W US 2021017866W WO 2021163490 A1 WO2021163490 A1 WO 2021163490A1
Authority
WO
WIPO (PCT)
Prior art keywords
gram
transgenic
negative bacterium
target
negative
Prior art date
Application number
PCT/US2021/017866
Other languages
English (en)
Inventor
Esteban Martinez
Victor DE LORENZO
Joseph D. Mougous
Snow Brook PETERSON
See-Yeun TING
Original Assignee
University Of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Washington filed Critical University Of Washington
Publication of WO2021163490A1 publication Critical patent/WO2021163490A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Abstract

La présente invention concerne des bactéries Gram-négatives transgéniques caractérisées par un système de sécrétion de type VI fonctionnel et qui exprime au moins un réactif d'affinité hétérologue qui se lie spécifiquement à un antigène de surface sur une bactérie Gram-négative cible. Dans un mode de réalisation illustratif, le réactif d'affinité est un anticorps à domaine unique (nanocorps). La bactérie cible est habituellement une espèce ou une souche différente de la bactérie transgénique. L'antigène de surface peut être caractérisé comme étant sensiblement unique à la bactérie cible, par exemple, dans le contexte d'une population hétérologue (par exemple, un microbiote intestinal). L'invention concerne également des compositions associées (par exemple, des compositions probiotiques) et un procédé de traitement et d'appauvrissement sélectif d'une bactérie Gram-négative cible dans une variété d'environnements.
PCT/US2021/017866 2020-02-14 2021-02-12 Appauvrissement ciblé de bactéries à partir de populations mélangées par l'intermédiaire d'une adhérence cellulaire programmable WO2021163490A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062976885P 2020-02-14 2020-02-14
US62/976,885 2020-02-14

Publications (1)

Publication Number Publication Date
WO2021163490A1 true WO2021163490A1 (fr) 2021-08-19

Family

ID=77292838

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/017866 WO2021163490A1 (fr) 2020-02-14 2021-02-12 Appauvrissement ciblé de bactéries à partir de populations mélangées par l'intermédiaire d'une adhérence cellulaire programmable

Country Status (1)

Country Link
WO (1) WO2021163490A1 (fr)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110311499A1 (en) * 2009-12-16 2011-12-22 University Of Washington Through Its Center For Commercialization Secretion System and Methods for its Use
US20120058907A1 (en) * 2004-01-20 2012-03-08 Merus B.V. Mixtures of binding proteins
US20120093870A1 (en) * 2009-06-30 2012-04-19 Stc.Unm Attenuated enterohemorrhagic e.coli-based vaccine vector and methods relating thereto
US20170174762A1 (en) * 2015-12-04 2017-06-22 Boehringer Ingelheim International Gmbh Biparatopic polypeptides antagonizing wnt signaling in tumor cells
US20180273956A1 (en) * 2014-12-22 2018-09-27 Synlogic, Inc. Bacteria Engineered to Treat Diseases that Benefit from Reduced Gut Inflammation and/or Tighten Gut Mucosal Barrier
US20180327481A1 (en) * 2013-11-04 2018-11-15 Inserm (Institut National De La Sante Et De La Recherche Medicale) Synthetic Single Domain Antibody
WO2018233624A1 (fr) * 2017-06-20 2018-12-27 和迈生物科技有限公司 Nanocorps anti-her2, séquence de codage et utilisation associée
US20190031743A1 (en) * 2016-01-29 2019-01-31 Achaogen, Inc. Screening methods for identifying antibodies that bind cell surface epitopes
US20190282628A1 (en) * 2016-01-11 2019-09-19 Synlogic Inc. Recombinant bacteria engineered to treat diseases and disorders associated with amino acid metabolism and methods of use thereof
US20190336544A1 (en) * 2017-01-06 2019-11-07 Synlogic Operating Company, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120058907A1 (en) * 2004-01-20 2012-03-08 Merus B.V. Mixtures of binding proteins
US20120093870A1 (en) * 2009-06-30 2012-04-19 Stc.Unm Attenuated enterohemorrhagic e.coli-based vaccine vector and methods relating thereto
US20110311499A1 (en) * 2009-12-16 2011-12-22 University Of Washington Through Its Center For Commercialization Secretion System and Methods for its Use
US20180327481A1 (en) * 2013-11-04 2018-11-15 Inserm (Institut National De La Sante Et De La Recherche Medicale) Synthetic Single Domain Antibody
US20180273956A1 (en) * 2014-12-22 2018-09-27 Synlogic, Inc. Bacteria Engineered to Treat Diseases that Benefit from Reduced Gut Inflammation and/or Tighten Gut Mucosal Barrier
US20170174762A1 (en) * 2015-12-04 2017-06-22 Boehringer Ingelheim International Gmbh Biparatopic polypeptides antagonizing wnt signaling in tumor cells
US20190282628A1 (en) * 2016-01-11 2019-09-19 Synlogic Inc. Recombinant bacteria engineered to treat diseases and disorders associated with amino acid metabolism and methods of use thereof
US20190031743A1 (en) * 2016-01-29 2019-01-31 Achaogen, Inc. Screening methods for identifying antibodies that bind cell surface epitopes
US20190336544A1 (en) * 2017-01-06 2019-11-07 Synlogic Operating Company, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
WO2018233624A1 (fr) * 2017-06-20 2018-12-27 和迈生物科技有限公司 Nanocorps anti-her2, séquence de codage et utilisation associée

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KAUR ET AL.: "Identification of conformation-selective nanobodies against the membrane protein insertase BamA by an integrated structural biology approach", JOURNAL OF BIOMOLECULAR NMR, vol. 73, 9 May 2019 (2019-05-09), pages 375 - 384, XP036860587, DOI: 10.1007/s10858-019-00250-8 *

Similar Documents

Publication Publication Date Title
Ting et al. Targeted depletion of bacteria from mixed populations by programmable adhesion with antagonistic competitor cells
Kim et al. Characterization of Autoinducer-3 Structure and Biosynthesis in E. coli
Cavera et al. Bacteriocins and their position in the next wave of conventional antibiotics
Allwood et al. Strategies for intracellular survival of Burkholderia pseudomallei
Bliven et al. Evolution of bacterial pathogens within the human host
Frirdich et al. The Campylobacter jejuni helical to coccoid transition involves changes to peptidoglycan and the ability to elicit an immune response
Shabbir et al. The involvement of the Cas9 gene in virulence of Campylobacter jejuni
Möllerherm et al. Yersinia enterocolitica-mediated degradation of neutrophil extracellular traps (NETs)
Wu et al. A novel cell wall lipopeptide is important for biofilm formation and pathogenicity of Mycobacterium avium subspecies paratuberculosis
Maan et al. Resolving the conflict between antibiotic production and rapid growth by recognition of peptidoglycan of susceptible competitors
Cui et al. Cell-length heterogeneity: a population-level solution to growth/virulence trade-offs in the plant pathogen Dickeya dadantii
US11918610B2 (en) Methods for diagnosis and treatment of type 1 diabetes
Gelfat et al. Single domain antibodies against enteric pathogen virulence factors are active as curli fiber fusions on probiotic E. coli Nissle 1917
Ochoa et al. Virulence assessment of enterohepatic Helicobacter species carried by dogs using the wax moth larvae Galleria mellonella as infection model
WO2021163490A1 (fr) Appauvrissement ciblé de bactéries à partir de populations mélangées par l'intermédiaire d'une adhérence cellulaire programmable
Tavakolian et al. Localization of Staphylococcus inside the vacuole of Candida albicans by immunodetection and FISH
Wiradiputra et al. Toxin-antitoxin systems: a key role on persister formation in Salmonella enterica serovar typhimurium
Zhang et al. High rate of multidrug resistance and integrons in Escherichia coli isolates from diseased ducks in select regions of China
Callahan et al. Battle for the histones: a secreted bacterial sirtuin from Campylobacter jejuni activates neutrophils and induces inflammation during infection
Sulaiman Diagnosis of Pathogenic Microorganisms Causing Infectious Diseases
EP4296359A1 (fr) Composition pour la décomposition de la trypsine ou de tmprss2
Chen et al. Bacterial Swarmers exhibit a Protective Response to Intestinal Stress
Perez Plasmids, Immunity, and Phages of Gut Bacterium Eggerthella lenta
Schüler et al. Novel insights into phage biology of the pathogen Clostridioides difficile based on the active virome
Sikhosana Mycobacterium amidases: Biological function and putative role in cell wall remodeling

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21754444

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21754444

Country of ref document: EP

Kind code of ref document: A1